ストックスクリーナーアプリを入手
10.01
1.67%
-0.17
アフターアワーズ：
10.30
0.29
+2.90%
前日終値:
$10.18
開ける：
$10.33
24時間の取引高:
1.03M
Relative Volume:
0.32
時価総額：
$1.61B
収益：
$68.56M
当期純損益:
$-437.99M
株価収益率:
-3.1638
EPS:
-3.1639
ネットキャッシュフロー:
$-396.61M
1週間 パフォーマンス:
-2.63%
1か月 パフォーマンス:
+10.49%
6か月 パフォーマンス:
+85.37%
1年 パフォーマンス:
+62.76%
1日の値動き範囲:
$9.90
$10.45
1週間の範囲:
$9.90
$10.45
52週間の値動き範囲:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.01 | 1.64B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | 開始されました | Evercore ISI | Outperform |
| 2025-08-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Vir Biotechnology Q1 2026 earnings preview - MSN
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology schedules CEO fireside chat at major healthcare event - Traders Union
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference - marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
Vir Biotechnology director Vicki Sato sells $221,025 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology director Vicki Sato sells $221,025 in stock - Investing.com
Vir Biotechnology (VIR) director sells 22,000 shares under 10b5-1 plan - Stock Titan
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vir Biotechnology (VIR) CEO shifts 467,064 shares into family trust - Stock Titan
Vir Biotechnology | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Insider resale notice: Company (NASDAQ: VIR) plans common stock sales - Stock Titan
Vir Biotechnology prices $150M stock offering - MSN
[SCHEDULE 13G] Vir Biotechnology, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration - Yahoo Finance
Vir Biotechnology (VIR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Brii Bio reports durable HCB control in Phase II analysis - The Pharma Letter
Vir Biotechnology launches $200M public stock offering - MSN
Certain Stock options of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com
Is VIR a Good Stock to Buy? - HarianBasis.co
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey
Certain Common Stock of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com
Press Release: Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - 富途牛牛
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - BioSpace
Vir Biotechnology to release Q1 2026 earnings on May 6 ahead of investor call - Traders Union
Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update - TipRanks
Vir Biotechnology Expands Oncology Pipeline via Astellas Partnership - HarianBasis.co
Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth - Insider Monkey
VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows - simplywall.st
Vir Biotechnology Doses First Patient in Prostate Cancer Clinical Trial - HarianBasis.co
Vir Biotechnology stock hits 52-week high at $10.94 By Investing.com - Investing.com Australia
Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year HighHere's Why - MarketBeat
Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? - insidermonkey.com
Vir Biotechnology stock hits 52-week high at $10.94 - Investing.com
Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In? - Insider Monkey
8 Best Low Priced Biotech Stocks to Invest In - Insider Monkey
Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a Potential 101% Upside in the Biotech Sector - DirectorsTalk Interviews
Vir Biotechnology, Inc. ($VIR) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Sanofi (SNY) Benefits from Vir Biotechnology's Collaboration wit - GuruFocus
Vir Biotechnology closes $240M Astellas deal for cancer drug By Investing.com - Investing.com Australia
Vir Biotechnology, Inc. Receives $240 Million Upfront Payment and $75 Million Equity Investment from Astellas - marketscreener.com
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatmen - PharmiWeb.com
Vir Biotechnology Completes Astellas Deal to Advance Prostate Cancer Immunotherapy - Contract Pharma
Vir Biotechnology (NASDAQ: VIR) sets 2026 meeting and pay vote - Stock Titan
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):